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Introduction
Management of papillary thyroid carcinoma (PTC) is challenging 
because the benefits and risks of available treatments are not clearly 
determined for this common endocrine malignancy [1]. Total 
thyroidectomy followed by radioactive iodine ablation (RIA) and 
with thyrotropin suppression therapy has been the mainstay of 
the management in the United States and Europe [2], although a 
“risk-adapted” approach has been advocated rather than a uniform 
application of the interventions. 
The guidelines for the management of thyroid cancer developed in 
Western countries served as useful references for Japanese physicinas 
as well, but the Japan Association of Endocrine Surgeons and the 
Japanese Society of Thyroid Surgery required their own guidelines 
for the following reasons: First, thyroid-conserving surgery, that is, 
less-extensive thyroidectomy, has been the most common operative 
procedure in Japan [3-9]. Second, the availability of RIA therapy 
has been quite limited because of legal restrictions and inadequate 
reimbursement of medical fees [4,5,10]. Third, adjuvant thyrotropin 
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suppression therapy has not been adopted as a routine treatment 
[4,5,10].
The Japanese experts classified PTC into three prognostic risk groups 
based on the preoperative (clinical) tumour–node–metastasis (TNM) 
system in their first guidelines for the management of thyroid tumours 
published in 2010. The groups are low-risk (T1N0M0), intermediate-
risk, and high-risk (tumour size > 5 cm, large metastatic lymph nodes > 
3 cm in diameter, extrathyroidal extension to the mucosa of the trachea 
or oesophagus, or distant metastasis) [6]. The experts recommended 
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lobectomy with prophylactic paratracheal lymph node dissection for 
patients with low-risk PTC and suggested total thyroidectomy (± lateral 
neck dissection) followed by RIA treatment and thyrotropin suppression 
therapy for high-risk patients. For the intermediate-risk group, the 
experts concluded that both lobectomy and total thyroidectomy are 
appropriate options as long as careful judgements are made for each 
patient; however, unique prognostic factors specific to this patient 
population were not provided in the guidelines.
This retrospective study was designed to examine the validity of the 
Japanese risk classification system, and to determine the clinical factors 
predicting oncological events in patients with intermediate-risk PTC.
Patients and methods
Study population
From the retrospective chart review, from among 454 patients who 
underwent their initial treatment for PTC between January 2000 and 
December 2004, we excluded 5 patients from the study because of a 
lack of relevant data (Figure 1). Each of the remaining 449 patients was 
classified into one of the three risk groups according to the Japanese 
Clinical Practice Guidelines. Distant metastasis was examined by chest 
X-ray, or neck and chest computed tomography. According to the 
diagnostic findings, patients were classified as low-, intermediate-, or 
high-risk [11].
Preoperative evaluations
In addition to physical examinations, ultrasonography as well as 
fine needle aspiration cytology of the suspected lesions was performed 
for all patients. Plain chest radiography was a routine preoperative test 
while computed tomographic scans of the neck and chest were indicated 
to examine local/regional tumour extension and distant metastases in 
select patients. Serum levels of thyrotropin, free triiodothyronine, free 
thyroxine, thyroglobulin, and anti-thyroglobulin antibody were also 
measured.
Treatment strategies
Subtotal thyroidectomy with either prophylactic or therapeutic 
lymph node dissection of the central and lateral neck regions was a 
standard surgical procedure for patients with PTC. For some patients 
who underwent total thyroidectomy because of advanced-stage disease, 
a diagnostic whole-body scan using 5 mCi of I-131 was performed as a 
postoperative evaluation. Patients with distant metastases received RIA 
therapy with 100 mCi I-131. Thyrotropin suppression therapy was used 
only for select patients.
Postoperative follow-up 
All patients were followed two or three times each year by 
both physical examinations and thyroid function testing, namely, 
thyrotropin, free triiodothyronine, free thyroxine, and thyroglobulin 
levels. Additionally, ultrasonography and computed tomography of the 
neck were used to confirm the presence or absence of cancer recurrence. 
Cancer recurrence was defined as both of local recurrence and distant 
metastasis after curative surgery.
Observations
We retrospectively reviewed patients’ medical records to collect 
the following data for each patient: age, sex, clinical TNM stage, 
intraoperative findings (e.g., extrathyroidal extension, extranodal 
extension, macroscopic curability), pathological TNM stage, serum 
levels of thyrotropin and thyroglobulin at each visit, the presence or 
absence of local/locoregional recurrence, presence or absence of distant 
metastasis, and survival. The primary outcome of this study was overall 
survival and disease-free survival (DFS), and the secondary outcome 
was cause-specific survival (CSS), with the day of surgery being 
time zero. The third outcome was identifying the risk factors in the 
intermediate group.
Statistical analyses
We estimated DFS and CSS using the Kaplan–Meier method. The 
log-rank test was used to examine differences between the risk groups 
as well as to identify potential prognostic factors. Cox’s proportional 
hazards regression modelling was used for multivariable analysis to 
determine the independent prognostic factors for DFS in patients 
with intermediate-risk PTC. The assumption of proportionality was 
examined using log–log plot analysis. Hazard ratios were presented 
with their 95% confidence intervals (CI). All statistical tests were 
two-sided, and differences were considered statistically significant if 
P < 0.05. All statistical analyses were performed using JMP software 
(version 13; SAS Institute Japan Ltd., Tokyo, Japan). 
Ethical considerations
This study was approved by the Ethical Committee of Tokyo 
Women's Medical University (No. 4063), and the requirement to obtain 
informed consent was waived.
Results
Patients’ characteristics
The median follow-up was 117 months (range, 0-164 months). 
Patients’ clinical and pathological characteristics are shown in Table 1. 
The numbers of patients with low-, intermediate-, and high-risk PTC 
were 67 (15%), 347 (77%), and 35 (8%), respectively. The median age 
was 51 years, and female patients accounted for 76% of all patients. 
Neither data regarding RIA examination nor serum thyrotropin 
suppression therapy after total thyroidectomy were obtained in this 
study because of a lack of precise data. Extrathyroidal extension of the 
tumour and extranodal extension were recognized intraoperatively in 
31.6% and 1.1% of patients, respectively (Table 1).
Oncological events
Forty-two patients (9%) experienced PTC recurrence as a first-time 
oncological event, and 11 patients (2%) died from the disease (Table 2). 
Of the 33 patients who experienced recurrence in the intermediate-risk 
group, local recurrence, lymph node metastasis, and distant metastasis 
was observed in 4, 26, and 3 patients, respectively. The “recurrence” does 
not include the cases which had biochemical recurrence manifested by 
thyroglobulin only.
Overall, 5- and 10-year survival were 97.2% (95% CI: 95.0%–98.4%) 
and 95.0% (95% CI: 92.1%–96.8%), respectively (Figure 2). Five- and 
10-year DFS for the entire study population were 94.2% (95% CI: 91%–
96%) and 89.1% (95% CI: 85%–92%), respectively (Figure 3a). The 10-
year DFS for the low-, intermediate-, and high-risk groups was 100%, 
89% (95% CI: 84%–92%) and 74% (95% CI: 56%–87%), respectively (P 
<0.001; log-rank test; Figure 3b).
CSS values for all patients were 97.9% (95% CI: 96%–99%) at 
5 years and 96.6% (95% CI: 94%–98%) at 10 years (Figure 4a). The 
10-year CSS for the low-, intermediate-, and high-risk groups was 
100%, 95% (95% CI: 92.0%–97.0%) and 72% (95% CI: 54.2%–84.8%), 
Horiuchi K (2020) Prognosis and prognostic factors in patients with intermediate-risk papillary thyroid carcinoma defined by the Japanese clinical practice guidelines 
for thyroid tumours
 Volume 5: 3-6Otorhinolaryngol Head Neck Surg, 2020         doi: 10.15761/OHNS.1000234
All Low risk Intermediate risk High risk
Number 449 67 347 35
Male-Female 108: 341 9:58 78:269 21:14
Age (years) 51(16-86) 52 (22-73) 51 (16-86) 51(18-81)







Tumor size (mm) 19 (0-90) 11 (5-20) 21 (0-50) 40 (4-90)
pN(0/1a/1b) 118/114/216 67/0/0 45/112/189 6/2/27
PEx*(0/12/nodalEx/X) 301/87/55/5/2 67/0/0/0/0 221/84/40/1/1 13/3/15/4/1
M (0/1) 442/7 67/0 347/0 28/7
Thyroid resection 
Total/subtotal 163/286 12/55 128/219 27/8
Lymph node dissection**
Central only/lateral 144/302 51/16 89/258 4/31
Intraoperative findings 
Extrathyroidal extension/Extranodal extensions 142/5 0/0 124/1 18/4
Table 1. Patients and characteristics 
*Ex: Extra thyroidal extension.
Low risk Intermediate risk High risk Total
Number of patients 67 347 35
Recurrence 42 (9%)
Local recurrence 0 (0%) 4 (1%) 2 (7%) *
Lymph node metastasis 0 (0%) 26 (7%) 5 (18%) *
Distant metastasis 0 (0%) 3 (1%) 2 (6%) *
Death from PTC** 0 (0%) 4 (1%) 7 (20%) 11 (2%)
Table 2. Recurrence and death rates
*Recurrence rate was calculated in 28 patients with MO. **PTC: Papillary Thyroid 
Carcinoma.
Factors Hazard ratio 95% Confidence internal P-value
Male 2.41 1.14-4.90 0.0209*
Age >55 years 2.33 1.15-4.89 0.0189*
Tumour diameter
> 4 cm 3.14 1.35-6.67 0.0091*
Extra thyroidal or extra nodal 
extension 1.72 0.84-3.51 0.1295
Table 3. Cox proportional hazards model in the intermediate-risk group
* Statistically significant.
Figure 1. Patient selection algorithm
respectively (Figure 4b). There was no difference between the low- and 
intermediate-risk groups; however, high-risk patients had significantly 
worse CSS compared with the other two groups (P < 0.001).   
Prognostic factors for DFS in patients with intermediate-risk PTC
The Kaplan–Meier curves for DFS in patients with intermediate-
risk PTC indicated that male sex, age > 55 years, tumour size > 4 cm, 
and extrathyroidal extension were associated with worse prognosis 
while clinically node-positive status was not prognostic (Fig. 5). A 
Cox’s proportional hazards model with the four variables significant 
in the univariate analyses revealed that male sex (hazard ratio: 2.41, 
95% CI: 1.14–4.90), tumour size > 4 cm (hazard ratio: 3.14, 95% CI: 
1.35–6.67), and age > 55 years (hazard ratio: 2.33, 95% CI: 1.15–4.89) 
were significant independent factors predictive of DFS (Table 3). 
Discussion and conclusion
This was a retrospective study of the validity of the risk classification 
in the Japanese clinical guidelines for PTC. Overall survival and CSS in 
the three risk groups differed significantly, especially when comparing 
the low- and intermediate-risk groups with the high-risk group. Our 
results revealed that the surgical strategy for low- and high-risk groups 
suggested in the Japanese clinical guidelines were valid. Our results 
showed controversy of benefit with total thyroidectomy followed RIA 
therapy for patients with low-risk PTC according to the excellent 
prognosis in this group, even without RIA treatment. In contrast, total 
thyroidectomy + lateral neck dissection followed by RIA might be 
mandatory for high-risk PTC. Because our results revealed that DFS 
and CSS in both the low- and intermediate-risk groups were high, 
postoperative radioiodine ablation might be controversial for the 
patients with an intermediate-risk. 
An important part of our study was our attempt to determine the 
prognostic factors in the intermediate-risk group because this analysis 
has not been performed previously. Our results indicated a small benefit 
of postoperative RIA in patients with intermediate-risk PTC because 
they have an excellent prognosis, similar to the low-risk group. Even 
though only 57% of patients underwent total thyroidectomy followed 
by only 10 mCi iodine for RIA in the intermediate-risk group, 5- and 
10-year DFS were very high at 99% and 88.9%, respectively. Narrowing 
the CIs made these results reliable.
The Japanese surgical strategy for PTC differs from that in Western 
countries [3-5]. In particular, excellent results have been achieved for 
low-risk PTC even with hemithyroidectomy [6-8].
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Regarding postoperative thyrotropin suppression therapy, Sugitani 
et al. [10], reported no benefit for low-risk PTC. Given these findings, 
Japanese surgeons have attempted to perform risk-adapted surgery and 
postoperative treatment.
Several studies have reported the risk factors for differentiated 
thyroid cancer or PTC. Matsuzu et al. [7], reported that risk factors 
related to distant metastasis were age > 45 years, tumour size > 4 
cm, extrathyroidal invasion positive, and lymph node-positive [7]. 
Ito et al. [12] reported that the risk factors related to DFS for lymph 
node metastasis were age > 55 years, male sex, massive extrathyroidal 
extension, and tumour size > 3 cm [13]. Additionally, Barney et al. 
[14], revealed that factors related to CSS were tumour size > 4 cm 
and age > 45 years. Although there has been interest in the prognostic 
factors in PTC, we could not compare these studies’ results with our 
results because most studies included combined data for the low- and 
intermediate-risk groups. No reports analysed the prognostic factors 
exclusively for patients with intermediate risk. To our knowledge, 
ours is the first study to analyse the prognostic factors in patients with 
intermediate-risk PTC, even though this was a retrospective study. Our 
results revealed that the Japanese risk classification of PTC was very 
accurate regarding determining prognosis, and there was no evidence 
against the surgical strategy for low- and high-risk PTC in the Japanese 
guidelines. Our aim in this study was to evaluate the prognosis of 
the intermediate-risk group because no previous study has done 
so. Our results indicated that the prognostic factors in patients with 
intermediate-risk PTC were 1) male sex, 2) tumour size > 4 cm, and 3) 
age > 55 years. Interestingly, the prognostic factors of age > 55 years and 
tumour size > 4 cm in diameter were the same as results reported in the 
8th TNM classification [15]. Furthermore, although we did not analyse 
the efficacy of postoperative RIA for intermediate-risk patients, it is 
crucial to know if postoperative RIA is mandatory in this risk group. 
Several reports have evaluated the efficacy of ablation therapy after total 
thyroidectomy for differentiated thyroid cancer [16], and some reports 
concluded that ablation prolongs survival in these patients [17,18]. 
Lamartina et al. [19], performed a systematic review of the literature 
evaluating RIA for low-risk differentiated thyroid cancer and concluded 
that there was no evidence that RIA decreased the recurrence rate in 
patients with low- or intermediate-risk thyroid cancer. Schvartz et al. 
[20], also failed to prove any survival benefit of RIA for low-risk PTC. 
There are limitations in our study. First, this was a retrospective 
study, and the surgical strategy at the time of operation differed from 
Figure 2. Overall survival
Figure 3. Disease-free survival
Figure 4. Cause-specific survival
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the guidelines. Subtotal thyroidectomy was a standard surgical strategy 
for PTC and was performed most often in the high-risk group in 1990’s. 
Second, we classified the risk groups according to histopathological 
diagnosis. Patients should have been classified according to preoperative 
information, but there was insufficient preoperative information to do 
so. Third, the intermediate group in the Japanese classification system 
differs from that of the American Thyroid Association [2]. Basically, 
the Japanese risk classification is determined according to preoperative 
information as for decision making regarding the surgical strategy 
(lobectomy or thyroidectomy), but the American Thyroid Association’s 
classification requires pathological information and demonstrates 
continuum of risk the low and intermediate groups.
We have a future perspective. In December 2018, the Japanese 
Association of Endocrine Surgery announced revised guidelines, and we 
plan to analyse our data according to the new guidelines, in the near future. 
References
1. Seib CD, Sosa JA (2019) Evolving Understanding of the Epidemiology of Thyroid 
Cancer. Endocrinol Metab Clin North Am 48: 23-35. [Crossref]
2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. (2016) 
2015 American Thyroid Association Management Guidelines for Adult Patients 
with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid 
Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid 
Cancer. Thyroid 26: 1-133. [Crossref]
3. Noguchi S, Murakami N, Kawamoto H (1994) Classification of papillary cancer of 
the thyroid based on prognosis. World J Surg 18: 552-557; discussion 558. [Crossref]
4. Shigematsu N, Takami H, Ito N, Kubo A (2005) Nationwide survey on the treatment 
policy for well-differentiated thyroid cancer -- results of a questionnaire distributed at 
the 37th meeting of the Japanese Society of Thyroid Surgery. Endocr J 52: 479-491. 
[Crossref]
5. Shigematsu N, Takami H, Kubo A (2006) Unique treatment policy for well-
differentiated thyroid cancer in Japan: results of a questionnaire distributed to members 
of the Japanese Society of Thyroid Surgery and the International Association of 
Endocrine Surgeons. Endocr J 53: 829-839. [Crossref]
6. Ito Y, Masuoka H, Fukushima M, Inoue H, Kihara M, et al. (2010) Excellent prognosis 
of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent 
thyroidectomy and elective lymph node dissection without radioiodine therapy. World 
J Surg 34: 1285-1290. [Crossref]
7. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, et al. (2014) Thyroid 
lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. 
World J Surg 38: 68-79. [Crossref]
8. Ebina A, Sugitani I, Fujimoto Y, Yamada K (2014) Risk-adapted management of 
papillary thyroid carcinoma according to our own risk group classification system: is 
thyroid lobectomy the treatment of choice for low-risk patients? Surgery 156: 1579-
1588; discussion 1588-1579. 
9. Dong W, Horiuchi K, Tokumitsu H, Sakamoto A, Noguchi E, et al. (2019) Time-
Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons 
from a Long-Term Follow-Up. Thyroid 29: 802-808. [Crossref]
10. Sugitani I, Fujimoto Y (2010) Does postoperative thyrotropin suppression therapy truly 
decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J 
Clin Endocrinol Metab 95: 4576-4583. [Crossref]
11. Takami H, Ito Y, Okamoto T, Yoshida A (2011) Therapeutic Strategy for Differentiated 
Thyroid Carcinoma in Japan Based on a Newly Established Guideline Managed 
by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine 
Surgeons. World J Surg 35: 111-121. [Crossref]
12. Ito Y, Miyauchi A, Jikuzono T, Higashiyama T, Takamura Y, et al. (2017) Risk factors 
contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/
AJCC TNM classification and stage grouping. World J Surg 31: 838-848. [Crossref]
13. Ito Y, Hirokawa M, Jikuzono T, Higashiyama T, Takamura Y, et al. (2007) Extranodal 
tumor extension to adjacent organs predicts a worse cause-specific survival in patients 
with papillary thyroid carcinoma. World J Surg 31: 1194-1201. [Crossref]
14. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD (2011) Overall and cause-
specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy 
for differentiated thyroid cancer. Head Neck 33: 645-649. [Crossref]
15. Tuttle RM, Haugen B, Perrier ND (2017) Updated American Joint Committee on Cancer/
Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer 
(Eighth Edition): What Changed and Why? Thyroid 27: 751-756. [Crossref]
16. Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, et al. (2011) Delayed initial 
radioactive iodine therapy resulted in poor survival in patients with metastatic 
differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl 
Med 52: 683-689. [Crossref]
Figure 5. Prognostic factors for disease-free survival in the intermediate-risk group
Horiuchi K (2020) Prognosis and prognostic factors in patients with intermediate-risk papillary thyroid carcinoma defined by the Japanese clinical practice guidelines 
for thyroid tumours
 Volume 5: 6-6Otorhinolaryngol Head Neck Surg, 2020         doi: 10.15761/OHNS.1000234
Copyright: ©2020 Horiuchi K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and source are credited.
17. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, et al. (2004) 
Clinical review 170: A systematic review and metaanalysis of the effectiveness of 
radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin 
Endocrinol Metab 89: 3668-3676. [Crossref]
18. Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, et al. (2015) Adjuvant radioactive 
iodine therapy is associated with improved survival for patients with intermediate-risk 
papillary thyroid cancer. J Clin Endocrinol Metab 100: 1529-1536. [Crossref]
19. Lamartina L, Durante C, Filetti S, Cooper DS (2015) Low-risk differentiated thyroid 
cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin 
Endocrinol Metab 100: 1748-1761. [Crossref]
20. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, et al. (2012) Impact on 
overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. 
J Clin Endocrinol Metab 97: 1526-1535. [Crossref]
